Expert Review of Hematology

Papers
(The H4-Index of Expert Review of Hematology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP52
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon51
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome42
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis34
Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management32
CD123-targeted therapy in acute myeloid leukemia26
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly24
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis24
Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic24
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia23
Do we need more guidance on thrombophilia testing? Challenges and special considerations21
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management21
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care21
The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas20
What is the future of digital tools to help manage pain in sickle cell disease patients?20
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma19
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases18
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease18
0.10148811340332